文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

131I-GMIB-抗HER2-VHH1的I期试验:乳腺癌HER2靶向放射性核素治疗新候选药物

Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.
PubMed 文献 · J Nucl Med · 2020-12-04

该I期研究在6名健康志愿者和3名HER2阳性转移性乳腺癌患者中评估了131I-GMIB-抗HER2-VHH1的安全性、生物分布、辐射剂量学和肿瘤显像潜力。研究未观察到药物相关不良事件,药物主要经肾脏清除,肾脏吸收剂量为1.54 ± 0.25 mGy/MBq,骨髓为0.03 ± 0.01 mGy/MBq,SPECT/CT显示转移灶局灶性摄取。

要点

  • 未观察到药物相关不良事件,安全性良好。
  • 肾脏吸收剂量1.54 ± 0.25 mGy/MBq,骨髓0.03 ± 0.01 mGy/MBq。
  • SPECT/CT显示HER2阳性转移灶局灶性摄取。

核心结论

  • 该放射性药物毒性特征良好且在HER2阳性病灶中有摄取,可能为曲妥珠单抗、帕妥珠单抗或T-DM1治疗后进展的患者提供新的治疗选择。

研究设计与样本

  • I期研究,第一队列纳入6名健康志愿者,第二队列纳入3名HER2阳性转移性乳腺癌患者。
  • 健康志愿者静脉注射38 ± 9 MBq的131I-GMIB-抗HER2-VHH1,于40分钟及2、4、24、72小时行全身平面显像,用OLINDA/EXM软件分析剂量学,并采集72小时血尿样本。
  • 乳腺癌患者于注射后2和24小时行全身平面显像,若已知病灶有相关摄取则加做SPECT/CT。

主要发现

  • 整个研究未观察到药物相关不良事件。
  • 健康受试者中131I-GMIB-抗HER2-VHH1的生物半衰期约8小时,血液清除半衰期为2.5小时,主要经肾脏消除。
  • 药物在循环中稳定,甲状腺或胃无增加蓄积。
  • 晚期乳腺癌患者SPECT/CT显示131I-GMIB-抗HER2-VHH1在转移灶中局灶性摄取。

关键数值与推荐

  • 肾脏吸收剂量为1.54 ± 0.25 mGy/MBq,骨髓为0.03 ± 0.01 mGy/MBq。
  • 后续I/II期研究计划进行剂量递增以评估治疗窗(NCT04467515)。

临床怎么用

  • 该药物安全性良好且能靶向HER2阳性转移灶,可能为HER2靶向治疗进展后的患者提供新选择。
  • 后续需剂量递增研究确定治疗窗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

131I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a targeted radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single-domain antibody covalently linked to therapeutic 131I via the linker N-succinimidyl 4-guanidino-methyl-3-iodobenzoate (SGMIB). The phase I study was aimed at evaluating the safety, biodistribution, radiation dosimetry, and tumor-imaging potential of 131I-GMIB-anti-HER2-VHH1 in healthy volunteers and breast cancer patients. Methods: In a first cohort, 6 healthy volunteers were included. The biodistribution of 131I-GMIB-anti-HER2-VHH1 was assessed using whole-body (anterior and posterior) planar images obtained at 40 min and at 2, 4, 24, and 72 h after intravenously administered (38 ± 9 MBq) 131I-GMIB-anti-HER2-VHH1. Imaging data were analyzed using OLINDA/EXM software to determine the dosimetry. Blood and urine samples were obtained over 72 h. In the second cohort, 3 patients with metastatic HER2-positive breast cancer were included. Planar whole-body imaging was performed at 2 and 24 h after injection. Additional SPECT/CT images were obtained after the whole-body images at 2 and 24 h if there was relevant uptake in known cancer lesions. Results: No drug-related adverse events were observed throughout the study. The biologic half-life of 131I-GMIB-anti-HER2-VHH1 in healthy subjects was about 8 h. After intravenous administration, the compound was eliminated from the blood with a 2.5-h half-life. The drug was eliminated primarily via the kidneys. The drug was stable in circulation, and there was no increased accumulation in the thyroid or stomach. The absorbed dose to the kidneys was 1.54 ± 0.25 mGy/MBq, and to bone marrow it was 0.03 ± 0.01 mGy/MBq. SPECT/CT imaging in patients with advanced breast cancer showed focal uptake of 131I-GMIB-anti-HER2-VHH1 in metastatic lesions. Conclusion: Because of its favorable toxicity profile and its uptake in HER2-positive lesions, this radiopharmaceutical can offer new therapeutic options to patients who have progressed on trastuzumab, pertuzumab, or trastuzmab emtansine, given its difference in mode-of-action. A dose escalation is planned in a subsequent phase I/II study to assess the therapeutic window of this compound (NCT04467515).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. D'Huyvetter M, Vos J, Caveliers V, et al. Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. J Nucl Med. 2020. PMID: 33277400. doi:10.2967/jnumed.120.255679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。